- Home
- /
- Retatrutide 10mg
Retatrutide 10mg
Certificate of Analysis
HPLC + Mass Spectrometry included with order
Retatrutide (LY3437943) is a first-in-class triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon (GCGR) receptors. This triple agonism represents the next evolution beyond dual agonists like Tirzepatide, adding glucagon receptor activation to enhance energy expenditure and hepatic fat metabolism.
Early clinical trial data (Phase 2) demonstrated unprecedented results in body weight reduction and metabolic parameters, generating significant research interest. Retatrutide is currently in Phase 3 clinical trials conducted by Eli Lilly and represents one of the most anticipated compounds in the metabolic research pipeline.
Kyrolab stocks Retatrutide across 5 dosage variants from 10mg to 50mg with independent verification across 4 different suppliers — more cross-supplier verification than any other product in our catalogue.
Dual-supplier verified:
Allen Bio: 99.430% purity, 11.58mg actual — Janoshik #68910 (Key:
46EBW6PAGUP3)WKC: 99.216% purity, 10.99mg actual — Janoshik #87697 (Key:
2LYACNT91MZB)
Specifications
| Molecular Weight | 4626.22 g/mol |
| CAS | 2381089-83-2 |
| Receptor | Triple agonist: GLP-1R + GIPR + GCGR |
| Developer | Eli Lilly (Phase 3 trials) |
| Appearance | White lyophilised powder |
| Storage | 2-8°C, protect from light |
| Dose | 10mg per vial |
This product is sold strictly for in-vitro research and laboratory purposes. Not for human or animal consumption. Not evaluated by the MHRA or FDA. Must be 18+ to purchase. By purchasing, you agree to our Research Disclaimer and Terms of Service.
| Catalogue Number | KYR-RETATRUTIDE10MG |
| Compound Name | Retatrutide 10mg |